Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is the OS count at this time . thanks
Awesome lets keep spreading the work about this awesome company . How soon will we get an update on trials?
what news should we expect short term . update on trials? LETS SPREAD THE WORD ABOUT THIS DEVICE. I KEEP FORWARDING THEIR VIDEO TO AS MANY PEOPLE AS I CAN . VERY INTERESTING COMPANY. SORRY FOR CAPS .
So in your opinion (others can chime in also) where do we see the sp being at upon fda approval and also after product launch. TIA. Also someone said they might do an ipo. how does that work with already public company. holding for a long term at least till product launch to hopefully if I sp does appreciate I take advantage of long term gain .
lets keep it up like today .
definetly testing some peoples patience but this is a long term play . holding for approval. should hear some news on testing this week .
Should be starting to get interesting in next couple of months. study will not take that long . and than bammmmm. up we go. UP A LOT!!!!!
Any body out there. hello!!!!!!!!
I would rather wait littler longer and have better product that could accually compete with isrg or be better . Rather than rush and maybe not even get FDA. We are almost there . Let these guys work. We cant change that . Only thing u can do if u are impatient is sell and forget about sport if it bothers u so much . its all good. 11out
Seeing how fast they got the IRB tells me that they have some smart people on their team making sure all is filled correctly to there is no back and fort going on with application . good to see . lets go lxgtf .
VANCOUVER, British Columbia, Jan 24, 2018 (GLOBE NEWSWIRE via COMTEX) --
Lexington Biosciences, Inc. (cse:LNB) (otcqb:LXGTF) (the "Company" or "Lexington"), a development-stage medical device company, is pleased to announce its recent application for Institutional Review Board ("IRB") approval of its pilot clinical study at Diablo Clinical Research has been approved.
As previously noted, approval by an IRB, or ethics board, is necessary before human research can begin. The IRB has reviewed Lexington's submission for both medical safety and protection of the patients involved in the study and has subsequently advised of its approval as submitted. With approval in-hand, the Company has engaged a clinical investigative team and research site in preparation for the process of volunteer enrollment.
Lexington's President Eric Willis comments, "The rapid approval of our clinical study submission speaks volumes to our team's diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself. We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead."
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.
About Lexington Biosciences, Inc. (cse:LNB / OTCQB)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
On Behalf of the Board,
"Eric Willis"
Eric Willis
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
CONTACT:
Lexington Biosciences, Inc.
+1 (800) 320-2640
info@lexingtonbiosciences.com
www.lexingtonbiosciences.com
Renmark Financial Communications Inc.
Laura Welsh: lwelsh@renmarkfinancial.com
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com
Talked with roger today. Ok. So the company does not have to release anything pass 30 day safety check up for low dose patients and the requlators dont require them to . Roger said _quote_(tlt is not required to release 6 month followup but We MAY release it. )he meant efficiency . I took it as they will release it soon. And also 90 day follow up for 4th patient. As far as rest of patient being treated they will pr once rest of 9 patients are treated. They do quaterly updates with UHN . Maybe all but just one left to get treated. Couldnt share that with me. Since only canadian patients are being screened and only one site it takes longer to get patients to meet criteria. Sounded like everything is on track. The research team is not a bunch impatient investors. They make sure it gets done correcly with no complications. The end of conversation was my favorite . RW Quote. (There shoud be lots of info coming out of the company soon and we shoud be VERY happy with the news)end quote. I personally think we will get some good news soon. Meaning within next couple of weeks. Imo.
Read more at http://www.stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=26839260#ofJlPVehDUM43Fio.99
U mean j&j-google robot? :)
NO its just the begining. They will sell their robot. Sport is propably still 2 years away from where trxc is today. I like them both
New 3rd Q Powerpoint Presentation[/url]
http://theralase.com/download-view/theralase-corporate-presentation-3q-2017/
page 4 - New cancer indication Phase 1b trial to commence 4Q2017
GBM trial?
stockhouse.podbean.com/e/podcast-47-theralase-technologies/
Memories. O yea. We were so pumped back then.
OT. Everyone should look into TLTFF. Human trials ongoing.
Dont get me wrong. I take chances on startups and titan trade made me good when it ran from
.30s to almost 2.50. There is lot of cheap stocks out there. Does not mean they will make profit. Same goes for titan. There is a reason it dropped to a dime and the inventor of sport just left and not involved anymore:(
After the rs when dust settles . Dont invest on hopes and dreams.
How many times were they done already?
Big conspiracy is that everybody at VERB is just sitying on their hands and waiting on titan to finish. Not working on anything at all. ? What do they do all day?
Bcg side effects Table 1
Side Effects Complications
Dysuria Urinary Tract Infection
Urgency Epididymitis/Orchitis
Frequency Abscess formation
Malaise Hematuria with clot retention
Arthralgia/Flu-like symptoms Fever >101.3 degrees F (38.5°C)
Low-grade Fever/chills Myelosuppression
Skin Rash/eruptions Ureteral obstruction
Anorexia Bladder contracture/necrosis
Nausea/Vomiting BCG Sepsis
Urinary Incontinence Neutropenia
Bladder Spasms Tissue necrosis with extravasation
Hematuria Pneumonitis
Hepatitis
Death
No way
Use to be a shareholder but this company has great potential
. Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
Toronto, Ontario – August 1, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fourth patient was treated, utilizing the Therapeutic Dose (0.70 mg/cm2) on July 20, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology.
These patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Gurin (“BCG”) course of treatments.
The Phase Ib NMIBC clinical study (“Study”) is entitled “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Gurin (“BCG”) and Who are Medically Unfit for or Refuse a Cystectomy”.
The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.
The Study is being used to evaluate TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.
The Study has demonstrated success in the treatment of the first 3 patients at the Maximum Recommended Starting Dose (“MRSD”) of the PDC (0.35 mg/cm2) and achieved the primary, secondary and exploratory endpoints at the 90 day cystoscopy analysis timepoint.
The exploratory outcome endpoint in the Study is Recurrence-Free Survival (“RFS”), defined as the interval from Day 0 (Day of treatment with TLD-1433 Photo Dynamic Therapy (“PDT”)) to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e. any biopsy-confirmed new or recurrent tumour), evaluated at ninety (90) days for the first three (3) patients treated at the MRSD (0.35 mg/cm2) and primarily at ninety (90) days for the next six (6) patients treated at the Therapeutic Dose (0.70 mg/cm2) and secondarily at one hundred and eighty (180) days post treatment.
Patient number 4 represents the first of an additional 6 patients to be enrolled and treated in the Study at the Therapeutic Dose of the PDC and evaluated according to the approved clinical protocol.
Roger Dumoulin-White, President and CEO of Theralase stated that, “The Company is pleased that it has successfully executed on the first part of the Study and has now advanced to the second part of the Study; specifically, the enrollment and treatment of an additional 6 patients at the Therapeutic Dose of the PDC. Theralase looks forward to successfully executing on the second part of the Study and will report out on its progress, as appropriate.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com
Read more at http://www.stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=26532160#DoJOqWl7lluHEj7V.99
Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
Toronto, Ontario – August 1, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fourth patient was treated, utilizing the Therapeutic Dose (0.70 mg/cm2) on July 20, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology.
These patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Gurin (“BCG”) course of treatments.
The Phase Ib NMIBC clinical study (“Study”) is entitled “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Gurin (“BCG”) and Who are Medically Unfit for or Refuse a Cystectomy”.
The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.
The Study is being used to evaluate TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.
The Study has demonstrated success in the treatment of the first 3 patients at the Maximum Recommended Starting Dose (“MRSD”) of the PDC (0.35 mg/cm2) and achieved the primary, secondary and exploratory endpoints at the 90 day cystoscopy analysis timepoint.
The exploratory outcome endpoint in the Study is Recurrence-Free Survival (“RFS”), defined as the interval from Day 0 (Day of treatment with TLD-1433 Photo Dynamic Therapy (“PDT”)) to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e. any biopsy-confirmed new or recurrent tumour), evaluated at ninety (90) days for the first three (3) patients treated at the MRSD (0.35 mg/cm2) and primarily at ninety (90) days for the next six (6) patients treated at the Therapeutic Dose (0.70 mg/cm2) and secondarily at one hundred and eighty (180) days post treatment.
Patient number 4 represents the first of an additional 6 patients to be enrolled and treated in the Study at the Therapeutic Dose of the PDC and evaluated according to the approved clinical protocol.
Roger Dumoulin-White, President and CEO of Theralase stated that, “The Company is pleased that it has successfully executed on the first part of the Study and has now advanced to the second part of the Study; specifically, the enrollment and treatment of an additional 6 patients at the Therapeutic Dose of the PDC. Theralase looks forward to successfully executing on the second part of the Study and will report out on its progress, as appropriate.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com
Read more at http://www.stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=26532160#DoJOqWl7lluHEj7V.99
News. Nice.
Verb and j&j are working hard and have all the cash on hand for over 2 years now to produce their own robot. And after that they just simply gone come out and say that they wore not doing anything at all and they just gone accuire some company that been strugling for years and whoo kows if any progress is being done at this point due to lack of funds.? U guys think they gone unveil someone elses robot and not take credit for any work . What do they do all day. Propaby just sitting on their hands and waiting when titan finishes the sport. I just dont know about that. Titan would have been cashed up and ahead if verb or j&j were backing titans project. Just saying. Ps. I only own 2 shares some one will say.
:) !!!!!
Soul. Buy at .0002. Lets go soul
Also remember that Roger is the largest share holder and wants this to be a Great success so he can make a lot of money in the end.
What he said is they might just release pr after all 6 patients enrolled and treated. Not gone release each patient enrollment like they did with the first 3 patients. He Didn't say they did or did not treat high dose patients yet. If u ever followed any research companies ull know it takes time to enroll and schedule patients hospital and research team + doctors to perform procedure. It takes more than 1 month to do. Be patient:) or just call yourself. Its worth it if u are a investor here. I do all the time . He always takes my calls or calls back.
Just talked with Roger White. Good stuff. The data on 3 month follow up will be released if UHN allows it. Most likely only first patient (high dose) enrolment and treatment news will be released and another pr after all 6 are treated. Not like first 3. Will update moore soon. Driving;))
I remember after all that waiting the tlc2000 finally got aproved the pps jumped up like a penny on that news. That tells u not a lot of investors were and are here her for that.
Cancer research is the interest. I think they needed to clarify that and get that off their back before new serious investmet will be made by some one/partner? They dont want this to bite them in the ass later. Better to be in the open now. Glad to hear 3 patients doing VERY WELL. :) and other 6 patients are identified and being screned. Should hear about enrolement next week. I will be calling roger this week. He always takes my calls. If some one wants to sent me PM about details from agm. Greatly apreciate that.
Cant post on stock house. Cuin23 research is there and patients are beaing treated. Cant stop the news on that. Nobody cares about laser side imho. Sucks they cant hit those numbers. But thats life. Cancer is what i am here for. Monthly donor to St. Jude hospital. Feel so bad for those little kiddos. :( maybe this research can help a little. Without HEALTH nothing really matters or make one happy. Cheers. It will get better. I got some titxf for a flip. Lol
Right. And those people have inside info. What does that tell u. And they cant even fill the offering. Only min. Amount?
What is the cash burn. How far does 7 mil gets them? Got my bid at .01 :) hopefully it fills. 25% of the market cap and only 200k between all bod and officers:( pushing and shoving to get in line
Yea. Lol now they were limited. That is the excuse now?
Only 7 mil raised . And now what? Another raise continues.